Is TARS or TECH more undervalued in 2026?

CirclFi compares Tarsus Pharmaceuticals, Inc. (TARS) and Bio-Techne Corp (TECH) using 13 institutional-grade valuation models. TARS has a Quality of Company score of 6.2/10 while TECH scores 7.2/10.

Which is a better buy — TARS or TECH?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TARS and TECH valuations compare?

TARS at $59.54 and TECH at $50.84 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TARS vs TECH Valuation Comparison 2026 — Intrinsic Value Analysis

TARS

Biotechnology

Tarsus Pharmaceuticals, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$59.54

Last close

Models

12/13

Active

TECH

Biotechnology

Bio-Techne Corp

Quality

7.2

out of 10

Value Trap

SAFE

Price

$50.84

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	TARS Fair Value	TARS Upside	TECH Fair Value	TECH Upside
Bayesian DCF	Intrinsic	$12.81	-78.5%	$29.59	-41.8%
Earnings Power Value	Intrinsic	$27.01	-56.0%	$12.26	-75.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TARS vs TECH — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TARS vs TECH — Which Stock Is More Undervalued?

TECH scores higher with a 7.2/10 quality rating vs TARS's 6.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tarsus Pharmaceuticals, Inc. (TARS) and Bio-Techne Corp (TECH) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TARS currently trades at $59.54 with a QOC of 6.2/10, while TECH trades at $50.84 with a QOC of 7.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).